ThermoGenesis Names Dan Bessey Chief Financial Officer

ThermoGenesis Names Dan Bessey Chief Financial Officer

New Executive Has More Than 20 Years of Finance and Corporate Development

RANCHO CORDOVA, Calif., March 28, 2013 (GLOBE NEWSWIRE) -- ThermoGenesis Corp.
(Nasdaq:KOOL), a leading supplier of enabling technologies for the processing,
storage and administration of cell therapies, today said that Dan T. Bessey
has joined the Company as Chief Financial Officer. Bessey has more than 20
years of finance and accounting experience and most recently was Vice
President, Chief Financial Officer of SureWest Communications, a publically
traded telecommunications company that merged with Consolidated Communications
in mid-2012.

Bessey joined SureWest in 1995 and held several senior finance management
positions including Director, Corporate Finance; Controller; and Vice
President, Finance, before being named Chief Financial Officer in 2008. Prior
to joining SureWest, Bessey was associated with Ernst & Young, LLP. A
Certified Public Accountant, he holds a B.S. in Business
Administration/Accountancy from California State University, Sacramento.

"We are delighted to have Dan join ThermoGenesis. His breadth of experience in
a number of areas, including operations, strategic planning, finance
management and M&A, will be of great value as we continue to execute our
growth strategy. He also provides additional depth to our senior management
team and I look forward to his contributing in a number of key areas across
the Company," said Matthew Plavan, Chief Executive Officer.

"I am excited about the opportunity at ThermoGenesis, as it is at the
forefront of groundbreaking technologies in regenerative medicine," Bessey
said. "The Company has realized a number of important accomplishments over the
past year and significantly improved its financial position. In addition,
ThermoGenesis has a solid and achievable plan in place to realize growth and
enhanced stockholder value," he added.

About ThermoGenesis Corp.

ThermoGenesis Corp. ( is a leader in developing and
manufacturing automated blood processing systems and disposable products that
enable the manufacture, preservation and delivery of cell and tissue therapy
products. These include:

  *The BioArchive^® System, an automated cryogenic device, used by cord blood
    stem cell banks in more than 30 countries for cryopreserving and archiving
    cord blood stem cell units for transplant.
  *AXP^® AutoXpress^® Platform (AXP), a proprietary family of automated
    devices that includes the AXP and the MXP^® MarrowXpress^® and companion
    sterile blood processing disposables for harvesting stem cells in closed
    systems. The AXP device is used for the processing of cord blood. The MXP
    is used for the preparation of cell concentrates, including stem cells
    from bone marrow aspirates in the laboratory setting.
  *The Res-Q^® 60 BMC/PRP (Res-Q), a point-of-care system designed for the
    preparation of cell concentrates, including stem cells, from bone marrow
    aspirates and whole blood for platelet rich plasma (PRP).

The ThermoGenesis Corp. logo is available at

   This press release contains forward-looking statements.These statements
  involve risks and uncertainties that could cause actual outcomes to differ
materially from those contemplated by the forward-looking statements. Several
 factors including timing of FDA and foreign regulatory approvals, changes in
customer forecasts, our failure to meet customers' purchase order and quality
requirements, supply shortages, production delays, changes in the markets for
 customers' products, introduction timing and acceptance of our new products
 scheduled for fiscal year 2013, and introduction of competitive products and
   other factors beyond our control could result in a materially different
revenue outcome and/or in our failure to achieve the revenue levels we expect
  for fiscal 2013.A more complete description of these and other risks that
    could cause actual events to differ from the outcomes predicted by our
 forward-looking statements is set forth under the caption "Risk Factors" in
 our annual report on Form 10-K and other reports we file with the Securities
  and Exchange Commission from time to time, and you should consider each of
        those factors when evaluating the forward-looking statements.

CONTACT: ThermoGenesis Corp.
         Web site:
         Investor Relations
         +1-916-858-5107, or

ThermoGenesis Corp. Logo
Press spacebar to pause and continue. Press esc to stop.